Cefprozil medicinal composition

A technology of cefprozil and its composition, which is applied in the field of medicine, can solve the problem that the hardness of the tablet is difficult to meet the requirements of packaging and transportation, and achieve the effects of excellent dispersion uniformity, release properties, and excellent hardness

Active Publication Date: 2012-07-04
GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when the dispersion uniformity is qualified, the hardness of the t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cefprozil medicinal composition
  • Cefprozil medicinal composition
  • Cefprozil medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Dispersible tablets containing 250 mg of cefprozil (calculated as anhydrous substance) as the non-micronized active compound, the cefprozil active compound accounting for about 74% of the total tablet weight:

[0048] Cefprozil (as anhydrous substance) 250mg

[0049] Microcrystalline Cellulose 57mg

[0050] Pregelatinized starch 10mg

[0051] 3% hypromellose 50% alcohol solution 100ml

[0052] Crospovidone 17mg

[0053] Magnesium Stearate 3mg

[0054] Preparation method: Cefprozil, pregelatinized starch, microcrystalline cellulose, 40% crospovidone (6.8mg), granulate with the hypromellose ethanol solution, dry, then add the remaining crospovidone Lupovidone, Magnesium Stearate, Blended, Tabletted.

Embodiment 2

[0056] Dispersible tablets containing 250 mg of cefprozil (calculated as anhydrous substance) as the non-micronized active compound, the cefprozil active compound accounting for about 68% of the total tablet weight:

[0057] Cefprozil (as anhydrous substance) 250mg

[0058] Microcrystalline Cellulose 91.2mg

[0059] Pregelatinized Starch 4mg

[0060] 3% hypromellose 50% alcohol solution 100ml

[0061] Crospovidone 11mg

[0062] Magnesium Stearate 1.8mg

[0063] Preparation method: add 5.5 mg of crospovidone first (accounting for 50% of the total weight of crospovidone), and the others are the same as in Example 1.

Embodiment 3

[0065] Dispersible tablets containing 250 mg of cefprozil (calculated as anhydrous substance) as non-micronized active compound, the cefprozil active compound accounting for about 80% of the total tablet weight:

[0066] Cefprozil (as anhydrous substance) 250mg

[0067] Microcrystalline Cellulose 32mg

[0068] Pregelatinized Starch 4mg

[0069] 2% hypromellose 50% alcohol solution 80ml

[0070] Crospovidone 12mg

[0071] Magnesium Stearate 4mg

[0072] Preparation method: add 4.2 mg of crospovidone first (accounting for 35% of the total weight of crospovidone), and the others are the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Viscosityaaaaaaaaaa
Login to view more

Abstract

The invention relates to an anti-infection oral medicinal preparation and discloses a cefprozil medicinal composition. The cefprozil medicinal composition comprises cefprozil serving as an active ingredient, at least one filling agent, at least one disintegrating agent, at least one lubricating agent, 1 to 10 weight percent of pregelatinized starch and 0.5 to 2 weight percent of hydroxypropyl methylcellulose. The invention also relates to a preparation method for the preparation and application of the preparation to treatment for upper respiratory tract infection, lower respiratory tract infection and skin and skin soft tissue infection.

Description

technical field [0001] The invention relates to an oral pharmaceutical composition for treating upper respiratory tract infection, lower respiratory tract infection, skin and skin soft tissue infection, in particular to a pharmaceutical preparation containing cefprozil, pregelatinized starch, hypromellose and its The preparation method belongs to the technical field of medicine. Background technique [0002] Cefprozil is an antibacterial drug with the following structural formula: [0003] [0004] (6R,7R)-7-[(R)-2-amino-2-(p-hydroxy-phenyl)acetamido]-8-oxo-3-propene-5-thia-1-azabicyclo- (4,2,0)oct-2-ene-2-carboxylic acid monohydrate. [0005] This is a second-generation oral cephalosporin antibiotic with high efficiency, low toxicity, and enzyme resistance. It has strong antibacterial activity against Gram+ bacteria, Gram-bacteria, and anaerobic bacteria, especially anti-G+ bacteria. Coccus, Streptococcus pyogenes, and Staphylococcus aureus have stronger antibacterial...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/545A61K9/20A61P11/00A61P17/00
Inventor 陈矛朱少璇肖颖杨放
Owner GUANGZHOU BAIYUNSHAN PHARMA HLDG CO LTD BAIYUNSHAN PHARMA GENERAL FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap